PTC Therapeutics Stock Forecast, Price & News

PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

Is PTC Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTC Therapeutics stock.
View analyst ratings for PTC Therapeutics or view top-rated stocks.

How has PTC Therapeutics' stock price been impacted by Coronavirus?

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PTCT shares have decreased by 19.4% and is now trading at $37.93.
View which stocks have been most impacted by COVID-19.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for PTC Therapeutics.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.78) by $0.11. The biopharmaceutical company earned $139 million during the quarter, compared to analyst estimates of $118.87 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 169.13% and a negative net margin of 92.43%. The company's revenue was up 68.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.03) earnings per share.
View PTC Therapeutics' earnings history.

What price target have analysts set for PTCT?

10 brokers have issued 1-year price objectives for PTC Therapeutics' stock. Their forecasts range from $38.00 to $75.00. On average, they expect PTC Therapeutics' share price to reach $54.13 in the next twelve months. This suggests a possible upside of 42.7% from the stock's current price.
View analysts' price targets for PTC Therapeutics or view top-rated stocks among Wall Street analysts.

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the following people:

• Stuart Walter Peltz, Chief Executive Officer & Director
• Emily Hill, Chief Financial Officer
• Neil Gregory Almstead, Chief Technical Operations Officer
• Mark Jerome Pykett, Chief Scientific Officer
• Mark Elliott Boulding, Chief Legal Officer & Executive Vice President (LinkedIn Profile)

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics CEO Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among PTC Therapeutics' employees.

Who are some of PTC Therapeutics' key competitors?

Some companies that are related to PTC Therapeutics include Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Sarepta Therapeutics (SRPT), Grifols (GRFS), Legend Biotech (LEGN), Mirati Therapeutics (MRTX) and Biohaven Pharmaceutical (BHVN).
View all of PTCT's competitors.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (12.40%), BlackRock Inc. (9.20%), Franklin Resources Inc. (6.81%), Janus Henderson Group PLC (5.06%), Macquarie Group Ltd. (2.22%) and Geode Capital Management LLC (1.81%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends for PTC Therapeutics.

Which institutional investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Renaissance Technologies LLC, Natixis, Sectoral Asset Management Inc, and Caption Management LLC. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey, and Stuart Walter Peltz.
View insider buying and selling activity for PTC Therapeutics or view top insider-selling stocks.

Which institutional investors are buying PTC Therapeutics stock?

PTCT stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Macquarie Group Ltd., Asymmetry Capital Management L.P., Janus Henderson Group PLC, UBS Group AG, Russell Investments Group Ltd., Hsbc Holdings PLC, and Wellington Management Group LLP.
View insider buying and selling activity for PTC Therapeutics or or view top insider-buying stocks.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $37.93.

How much money does PTC Therapeutics make?

PTC Therapeutics has a market capitalization of $2.68 billion and generates $380.77 million in revenue each year. The biopharmaceutical company earns $-438.16 million in net income (profit) each year or ($6.48) on an earnings per share basis.

How many employees does PTC Therapeutics have?

PTC Therapeutics employs 963 workers across the globe.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is www.ptcbio.com.

Where are PTC Therapeutics' headquarters?

PTC Therapeutics is headquartered at 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at [email protected], or via fax at 908-222-7231.